OTCMKTS:RHHBY Roche (RHHBY) Stock Price, News & Analysis $50.50 -1.40 (-2.70%) As of 07/13/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesInsider TradesOwnershipShort InterestBuy This Stock About Roche Stock (OTCMKTS:RHHBY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Roche alerts:Sign Up Key Stats Today's Range$50.48▼$51.6250-Day Range$49.00▼$53.3452-Week Range$37.51▼$60.85Volume3.85 million shsAverage Volume1.64 million shsMarket Capitalization$321.71 billionP/E RatioN/ADividend Yield1.92%Price Target$51.50Consensus RatingHold Company Overview Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY). In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies. The diagnostics business supplies a broad range of in vitro and molecular diagnostics, tissue‑based pathology solutions, point‑of‑care testing and diabetes care products, along with instruments and assay systems used by hospitals, laboratories and clinics to support clinical decision‑making and patient monitoring. Roche has a global footprint with operations and research facilities across Europe, the Americas and Asia, and a portfolio that combines internally developed products with offerings from affiliated biotech subsidiaries. The company emphasizes research and development and partnerships to advance precision medicine, leveraging its diagnostics expertise to support the selection and monitoring of appropriate therapies.AI Generated. May Contain Errors. Read More Roche Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreRHHBY MarketRank™: Roche scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingHold Consensus RatingRoche has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on no strong buy ratings, 4 buy ratings, 7 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Roche is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageRoche has only been the subject of 2 research reports in the past 90 days.Read more about Roche's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth6.96% Earnings GrowthEarnings for Roche are expected to grow by 6.96% in the coming year, from $3.16 to $3.38 per share.Price to Earnings Growth RatioRoche has a PEG Ratio of 4.06. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoche has a P/B Ratio of 7.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Roche's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.06% of the float of Roche has been sold short.Short Interest Ratio / Days to CoverRoche has a short interest ratio ("days to cover") of 1.32, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Roche has recently decreased by 2.77%, indicating that investor sentiment is improving. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRoche pays a meaningful dividend of 1.87%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoche does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Roche will have a dividend payout ratio of 28.70% next year. This indicates that Roche will be able to sustain or increase its dividend.Read more about Roche's dividend. News and Social Media2.4 / 5News Sentiment-0.08 News SentimentRoche has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Roche this week, compared to 7 articles on an average week.Search Interest7 people have searched for RHHBY on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows12 people have added Roche to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Roche insiders have not sold or bought any company stock.Percentage Held by InstitutionsRoche has minimal institutional ownership at this time.Read more about Roche's insider trading history. Receive RHHBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roche and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RHHBY Stock News HeadlinesIonis extends losses as Roche scraps two partnered studiesJuly 10, 2026 | seekingalpha.comTeva, Polpharma ink licensing pact for biosimilar targeting Roche’s OcrevusJuly 9, 2026 | seekingalpha.comALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.July 14 at 1:00 AM | Brownstone Research (Ad)Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAICJuly 7, 2026 | finance.yahoo.comGenentech and Roche Present New Data in Alzheimer's Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAICJuly 7, 2026 | businesswire.comRoche presents new data in Alzheimer's disease from across its integrated pharmaceutical and diagnostics portfolio at AAICJuly 7, 2026 | globenewswire.com[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung ...July 2, 2026 | finance.yahoo.comRoche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage TrialJuly 2, 2026 | wsj.comSee More Headlines RHHBY Stock Analysis - Frequently Asked Questions How have RHHBY shares performed this year? Roche's stock was trading at $51.57 on January 1st, 2026. Since then, RHHBY stock has decreased by 2.1% and is now trading at $50.50. Does Roche have any subsidiaries? Roche subsidiaries include Inflazome, Stratos Genomics, Promedior, Spark Therapeutics, Tusk Therapeutics, Flatiron Health, Ignyta, and more. Who are Roche's major shareholders? Top institutional shareholders of Roche include GAMMA Investing LLC, Confluence Investment Management LLC and Fulton Bank N.A.. How do I buy shares of Roche? Shares of RHHBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/14/2026Next Earnings (Estimated)7/23/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Large Cap Pharma Sub-IndustryPersonal Services Current SymbolOTCMKTS:RHHBY CIKN/A Webwww.roche.com Phone(161) 688-1111Fax41-0-61-691-9391Employees103,249Year Founded1896Price Target and Rating Average Price Target for Roche$51.50 High Price Target$57.00 Low Price Target$46.00 Potential Upside/Downside+2.0%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E Ratio15.98 P/E Growth4.06Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.72 Current Ratio1.38 Quick Ratio1.12 Sales & Book Value Annual Sales$76.45 billion Price / Sales4.21 Cash Flow$3.50 per share Price / Cash Flow14.41 Book Value$7.18 per share Price / Book7.03Miscellaneous Outstanding Shares6,370,540,000Free FloatN/AMarket Cap$321.71 billion OptionableNot Optionable Beta0.50 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:RHHBY) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredForget SpaceX, this is Elon’s Next BreakthroughJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredYour money is changingPorter Stansberry - who warned readers about Fannie Mae in 2006, called gold in 2008, and predicted COVID-era ...Porter & Company | SponsoredThe $5 company SpaceX can’t survive withoutThe investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...Traders Agency | SponsoredTrump Set to Unleash 219-Year-Old “Super Weapon” on U.S. SoilFour-time U.S. Presidential advisor Jim Rickards is warning of a political move he calls 'The Trump Supremacy'...Paradigm Press | Sponsored60 years. Zero competitors.One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...Behind the Markets | SponsoredPrint this and keep it by your screenEver been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
